Robert Medairos
Urology · Durham, NCNPI 1639601644
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $26,803 with a category attached, or 93.3%. Boston Scientific accounts for 99.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $25,296 and has fallen 99.0% since, to $252 in 2025. Among urology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $992.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$27K
- Calyxo, Inc.$125
- Olympus Corporation Of The Americas$61
- Olympus America Inc.$58
- Novartis$22
What the payments were for
- Grants$25,00093%
- Food & beverage$1,8037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $26,536 |
| Calyxo, Inc. | 1 | $125 |
| Olympus Corporation Of The Americas | 1 | $61 |
| Olympus America Inc. | 1 | $58 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$25,000
- LithoVue$480
- ACCOLADE SR$127
- CVAC Aspiration System$125
- Moses 550 DFL$125
How this compares
$26,803 in reported general payments places this provider in the 90th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 126 | $19,441 |
| MyrbetriqMirabegron | 15 | $12,877 |
| Klor-Con-EfPotassium Bicarbonate/Cit Ac | 13 | $1,046 |
| Tamsulosin Hcl | 84 | $967 |
| Estradiol | 14 | $830 |
| Chlorthalidone | 44 | $595 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $263 |
| Finasteride | 16 | $243 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $219 |
| Indapamide | 14 | $147 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $102 |
| Tadalafil | 13 | $94 |
| Cephalexin | 18 | $86 |
Paid to pharmacies, not to this prescriber.
Other urology in Durham
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
- Jay KimDurham$202K
- Andrew PetersonDurham$124K
- Cary RobertsonDurham$76K
- Brant InmanDurham$55K
- Thomas PolascikDurham$54K
- Edward HouserDurham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.